Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4

Journal of Neuroimmunology

Volumn 111, Issue 1-2, 2000, Pages 86-92

  Furlan, Roberto ^a   Bergami, Alessandra ^a   Lang, Rosmarie ^b   Brambilla, Elena ^a   Franciotta, Diego ^c   Martinelli, Vittorlo ^a   Comi, Giancarlo ^a   Panina, Paola ^b   Martino, Gianvito ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b ROCHE MILANO RICERCHE   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Interferon ; Intracellular cytokine staining; Multiple sclerosis; T helper cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 4;

ADULT; ANTIGEN PRESENTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG ACTIVITY; FEMALE; FOLLOW UP; HELPER CELL; HUMAN; IMMUNOMODULATION; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADULT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMAN; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-4; KILLER CELLS, NATURAL; MALE; MIDDLE AGE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTORS, IGG; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0034333099     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00377-5     Document Type: Article

References (34)

1. Functional diversity of helper T lymphocytes
2. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy
3. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?
4. Mouse CD1-specific NK1 T cells: development, specificity, and function
5. Cytokine gene expression in cells derived from CSF of multiple sclerosis patients
6. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-lb
7. Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up
8. Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS
9. Th-cell modulation in multiple sclerosis
10. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon-β1b
11. Reduction of both pro- and anti-inflammatory cytokines after six months of interferon-beta la treatment of multiple sclerosis
12. Rating neurological impairment in MS. An expanded disability scale (EDSS)
13. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis
14. Proinflammatory cytokines regulate antigen-independent T cell activation by two separate calcium signaling pathways n multiple sclerosis patients
15. Immunopathogenesis of multiple sclerosis: the role of T cells
16. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development
17. The expanding universe of T-cell subsets: Th1, Th2 and more
18. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increase either during exacerbations or in response to IFN-beta treatment
19. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta lb (IFN-beta1b)
20. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations
21. Immunomodulatory effects of interferon-beta-1b in vivo: induction of the expression of transforming growth factor-beta1 and its receptor type II
22. Exacerbations of multiple sclerosis in patients treated with gamma interferon
23. Effect of IFNβ and anti-IFNβ antibodies on NK cells in multiple sclerosis patients
24. Interferon gamma producing blood lymphocytes are decreased by interferon-beta therapy in patients with multiple sclerosis
25. New diagnostic criteria for MS: guidelines for research protocols
26. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients
27. In vivo effects of interferon beta-i a on immunosuppressive cytokines in multiple sclerosis
28. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease
29. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions
30. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia
31. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis
32. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
33. Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma)
34. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS